vehicle gel (NFlection Therapeutics)

The vehicle gel developed by NFlection Therapeutics is a topical formulation used as a placebo control in clinical trials for the treatment of cutaneous neurofibromas (cNFs) associated with Neurofibromatosis Type 1 (NF1). It is specifically designed to serve as the comparator for NFX-179 Gel, a topical 'soft' MEK (mitogen-activated protein kinase kinase) inhibitor. The vehicle gel is composed of the same inactive ingredients as the active drug product but lacks the NFX-179 active pharmaceutical ingredient. Its primary purpose is to establish a baseline for safety, tolerability, and efficacy in randomized, double-blind, vehicle-controlled studies, such as the Phase 2a and Phase 2b trials conducted by NFlection Therapeutics. By matching the active drug's appearance, consistency, and application method, it ensures the blinding of participants and investigators during clinical evaluation.

Other names

Vehicle Control